JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v8i5.7305ArticleClinical Efficacy and Safety Analysis of Tigecycline in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Combined with Multidrug-Resistant Acinetobacter baumannii Infectionhttps://artdesignp.com/journal/JCNR/8/5/10.26689/jcnr.v8i5.7305WangHongbing2024852024-06-21Objective: To study the clinical efficacy and safety of tigecycline in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) combined with multidrug-resistant Acinetobacter baumannii infection. Methods: 113 patients with acute exacerbation of COPD combined with multidrug-resistant Acinetobacter baumannii infection were recruited between January 2021 and January 2023, and given tigecycline treatment. The total effective rate, lung function indexes, related biochemical index levels, and the incidence rate of adverse reactions were observed after the treatment. Results: After the treatment, 100 patients were cured, 1 case with apparent effect, 2 cases were effective, 10 cases were ineffective, and the total effective rate was 91.15%. The post-treatment CRP (21.22 ± 3.35 mg/L), PCT (3.18 ± 1.11 ng/L), CRE (76.36 ± 9.24 μmol/L), and ALT (37.76 ± 6.99 U/L) were significantly improved as compared to the pre-treatment (P < 0.05). After treatment, 10 cases of vomiting (8.85%), 13 cases of nausea (11.50%), 4 cases of diarrhea (3.53%), 1 case of abdominal pain (0.88%), and 2 cases of allergy (1.77%) were observed in 113 patients. Conclusion: Tigecycline therapy for patients with acute exacerbation of COPD combined with multidrug-resistant Acinetobacter baumannii infection not only has significant therapeutic efficacy but also has a high degree of safety.

Zhou HJ, Liang MY, Li YH, 2022, Observation on the Efficacy of Cefoperazone Sulbactam Combined with Tigecycline in the Treatment of Nosocomial Infection with Acinetobacter baumannii in COPD. Heilongjiang Medicine, 35(2): 337–339.

Fu Y, Chen C, Zhao J, et al., 2020, Efficacy of Compound Sulfamethoxazole Tablets Combined with Tigecycline in the Treatment of Multidrug-Resistant Bacterial Infections in COPD Patients. Jiangsu Medicine, 46(6): 623–626.

Xi J, Duo M, Wei Y, et al., 2020, Analysis of Pathogenic Bacteria Isolation and Drug Resistance in Lower Respiratory Tract Infections Complicated by COPD of Different Stages. Chinese Journal of Antibiotics, 45(8): 798–803.

Huang A, Tong J, 2019, Clinical Efficacy of Early Application of Tigecycline on Different Types of Severe Lung Infections. Modern Medicine and Health, 35(17): 2596–2599.

Wu A, Wu Y, 2019, Analysis of Pathogenic Bacteria Distribution and Antimicrobial Drug Resistance of VAP Infection Complicated by Mechanical Ventilation in COPD Patients. Nursing Research, 33(6): 1075–1077.

Zhang L, Zhang Q, Xu H, et al., 2021, Carbapenem-Resistant Klebsiella pneumoniae Drug Susceptibility and Genotype in Patients with COPD Combined with Lung Infection. Chinese Journal of Hospital Infection, 31(23): 3527–3531.

Huang D, Huang L, Zhang H, et al., 2022, Analysis of Bacterial Profiles and Drug Sensitivity in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Hebei Medicine, 28(11): 1921–1925.

Zhang D, 2020, Clinical Efficacy and Safety Observation of Tigecycline Combined with Isopamicin in the Treatment of Multi-Drug Resistant Acinetobacter baumannii Pneumonia. North Pharmacology, 17(6): 154–155.

Huang Q, Deng J, Wang S, 2022, Effect of Chronic Obstructive Pulmonary Disease on the Distribution and Drug Resistance of Pathogenic Bacteria in Pulmonary Infections. Practical Drugs and Clinics, 25(6): 512–516.

Yu F, Liu Y, Huang Z, 2022, Analysis of Factors Affecting Infection in Patients with Chronic Obstructive Pulmonary Disease with Acute Lower Respiratory Tract Infection. China Modern Physician, 60(28): 67–70.

Sun T, Li X, Li H, 2023, Distribution of Pathogenic Bacteria and Associated Risk Factors in Patients with Postoperative Lung Infection After Thyroid Cancer. Cancer Progress, 21(22): 2536–2539.

Wang H, Qin R, 2019, Clinical Analysis of Tigecycline Combined with Cefoperazone Sulbactam in the Treatment of Multi-Drug Resistant Acinetobacter baumannii Pneumonia. China Drugs and Clinics, 19(8): 2.

Chen J, Hu Z, Lin R, et al., 2020, Analysis of Risk Factors for Imipenem-Resistant Acinetobacter baumannii Infection in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Journal of Guangdong Medical University, 38(2): 181–184.

Li C, Yu F, Bao Q, 2023, Study on Pathogenic Bacteria and Drug Resistance of Lung Infection in Patients with Chronic Obstructive Pulmonary Disease. South China Preventive Medicine, 49(6): 743–746.

Zhou Y, Hu H, Zhang J, 2015, Observation on the Efficacy of Tigecycline Combined with Cefoperazone Sulbactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Pneumonia. Journal of Practical Medicine, 31(5): 3.